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Background: Protection against hepatitis B disease after
immunization is considered as relying on both the persis-
tence of protective serum antibodies and the ability of the
immune system to mount an anamnestic response when
rechallenged with the hepatitis B virus (HBV). Hexava-
lent DTPa-HBV-IPV/Hib vaccine (Infanrix hexaTM) has been
found to induce comparable seroprotective antibody levels
against hepatitis B as monovalent hepatitis B vaccines in the
short-term, and this study evaluated the long-term immune
memory towards HBV in children aged 4—5 years.
Methods: Open-label study [106789] conducted in 27
centres in Germany, enrolling children aged 4—5 years previ-
ously primed and boosted in routine clinical practice with 4
doses of DTPa-HBV-IPV/Hib vaccine. All subjects received a
single challenge dose of monovalent paediatric HBV vaccine
(EngerixTM-B Kinder; GSK Biologicals). Blood samples were
collected before and one month after vaccination. Anti-
HBs antibodies were measured using ELISA; a concentration
≥10mIU/ml was considered seroprotective.
Results: A total of 301 subjects were vaccinated, of whom
286 were included in the ATP cohort for immunogenicity.
Prior to challenge, 85.3% of subjects had anti-HBs antibod-
ies ≥10mIU/ml and 47.0% of subjects had concentrations
≥100mIU/ml. One month after the challenge, the percent-
ages of subjects increased to 98.3% and 95.8%, respectively.
Anti-HBs antibody Geometric Mean Concentrations rose 100-
fold from 88.7 to 8711.8mIU/ml. The HBV challenge vaccine
was well tolerated and no serious adverse events were
reported.
Conclusion: Primary and booster vaccination with Infan-
rix hexaTM in routine clinical practice induces long-term
seroprotection against hepatitis B and immune memory as
demonstrated by the strong response to HBV challenge.
doi:10.1016/j.ijid.2008.05.194
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Background: The introduction of oral live attenuated
human rotavirus vaccine RIX4414 (RotarixTM, GSK Bio-
logicals) into childhood immunisation schedules can be
facilitated by concomitant administration with routine
diphtheria-tetanus-whole cell pertussis (DTPw) vaccine
combinations. This multicentre trial (104021) assessed the
impact of co-administering RIX4414 vaccine on the immune
response to primary vaccination with two formulations of
DTPw-hepatitis B [DTPw-HBV (ZilbrixTM or TritanrixTM); GSK
Biologicals].
Methods: Healthy infants 11—17 weeks of age were
randomised to receive one of the following vaccination reg-
imens at 3, 4.5 and 6 months of age: RIX4414 vaccine
(3 and 4.5 months) + DTPw-HBV (ZilbrixTM or TritanrixTM);
RIX4414 placebo (3 and 4.5 months) + DTPw-HBV (ZilbrixTM
or TritanrixTM); separate DTPw (Triple AntigenTM; CSL) +HBV
(EngerixTM-B; GSK Biologicals) vaccines. Oral polio vac-
cine was administered concomitantly to all children. Blood
samples for immunogenicity analysis were obtained before
vaccination and one month after the third dose of DTPw
vaccine (Month 7). Solicited adverse events were recorded
on days 0—7 post-vaccination, unsolicited adverse events on
days 0—30 and serious adverse events throughout the entire
study.
Results: 308 subjects were enrolled and vaccinated,
of whom 302 and 254 were included in the ATP cohorts
for safety and immunogenicity, respectively. One month
after the third primary vaccination dose, (2.5 months
after the second RIX4414 dose), anti-rotavirus seroconver-
sion rates70.0—74.5% were seen in the 2 groups receiving
RIX4414. In the groups receiving DTPw-HBV combinations,
seroprotection against diphtheria, tetanus, hepatitis B,
poliovirus types 1, 2 and 3 and vaccine response to B. per-
tussis was seen in 100%, 100%, 100%, ≥97.3% and ≥96.2%
of subjects, respectively. No signiﬁcant increase in the
incidence of solicited adverse events was observed with co-
administration of the RIX4414 vaccine. All vaccine regimens
showed similar reactogenicity and safety proﬁle.
Conclusion: Co-administration of neither RIX4414
(RotarixTM) nor DTPw-HBV vaccines impacted on the
immune response of the other vaccine.
doi:10.1016/j.ijid.2008.05.195
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Objective: To evaluate the efﬁcacy of a single oral
azithromycin dose vs. standard oral erythromycin regimen
or no antibiotic for Campylobacter enterocolits in children
≤12 years of age.
Methods: Randomized parallel group assessor-blind trial.
Patients (N = 120) were enrolled ≤48 hours since disease
onset to receive erythromycin 50mg/kg/day over 5 days,
single-dose azithromycin 20mg/kg or 30mg/kg, or no
